On Monday, Principal Financial Group Inc(NYSE:PFG)’s shares declined -0.79% to $47.80.
Principal Financial Group, Inc. (PFG) recently declared results for second quarter 2015.
- Operating earnings raised to $323.9 million for second quarter 2015, contrast to $323.1 million for second quarter 2014. After adjusting for normalizing items and foreign exchange rates, operating earnings raised 10 percent over second quarter 2014. Operating earnings per diluted share (EPS) raised 1 percent to $1.09 for second quarter 2015, contrast to $1.08 for second quarter 2014.
- Net incomeaccessible to common stockholders for second quarter 2015 reduced to $241.1 million, or 81 cents per diluted share, contrast to $306.3 million, or $1.03 per diluted share for second quarter 2014.
- Operating revenuesraised 34 percent in second quarter 2015 to $3,406.8 million from higher sales and fee income, contrast to $2,542.6 million for second quarter 2014.
- Fee income3raised 6 percent to $908.5 million for the second quarter 2015, contrast to $855.3 million for second quarter 2014.
Principal Financial Group, Inc. provides retirement, asset administration, and insurance products and services. It operates through Retirement and Investor Services, Principal Global Investors, Principal International, and U.S. Insurance Solutions segments. The Retirement and Investor Services segment provides a portfolio of asset accumulation products and services for retirement savings and investment to businesses, institutional clients, and employees of business and other individuals.
DaVita HealthCare Partners Inc (NYSE:DVA)’s shares dropped -0.31% to $74.77.
DaVita HealthCare Partners Inc. (DVA), one of the largest and most innovative health care communities, declared recently that it has named Dinesh Kumar, M.D., senior vice president of clinical transformation. In this role, Dr. Kumar will leverage his passion for cost-effective, evidence-based care to drive efforts that take the proven care administration model of HealthCare Partners across the country. He takes on this new challenge after having been part of the HealthCare Partners family for over 14 years.
DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company offers outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and administration and administrative services to outpatient dialysis centers, in addition to patient and physician focused integrated health care delivery and administration services.
At the end of Monday’s trade, Stratasys, Ltd. (NASDAQ:SSYS)‘s shares surged 4.25% to $30.18.
Stratasys Asia Pacific, a partner of Stratasys Ltd. (SSYS), a global leader of 3D printing and additive manufacturing solutions, recently declared a customer story illustrating how Honda Access Co. Ltd. (“Honda Access”) of Honda, leverages 3D printing technology to gain competitive advantage with car accessories prototyped by Stratasys 3D printing system, thus improving the development efficiencies by synchronizing the development plan of automotive and car accessories.
Headquartered in Saitama Prefecture, Japan, Honda Access manufactures accessories for Honda’s cars, motorcycles and other items globally, designing up to 300 accessories for each Honda car model for local buyers based on the requirements such as driver intention, climate and road surface conditions in different traffic conditions. To maximize customization efficiency, the company opted for a Stratasys Objet® Eden500V™ 3D printer in 2013, with the objective to accelerate the product development cycle, substituting the CNC machines.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts. Its AM systems utilize its patented fused deposition modeling and inkjet-based PolyJet technologies to enable the production of prototypes, tools used for production and manufactured goods directly from three-dimensional (3D) CAD files or other 3D content. The company offers entry-level desktop 3D printers for idea and design development, a range of systems for rapid prototyping, and production systems for direct digital manufacturing under the Dimension, Objet, Fortus, Polyjet, SolidScape, and MakerBot brands.
Theravance Inc (NASDAQ:THRX), ended its Monday’s trading session with -0.79% loss, and closed at $10.05.
Theravance, Inc. (NASDAQ:THRX) declared recently that Michael W. Aguiar, Theravance’s President and Chief Executive Officer, will present at the following event:
Morgan Stanley Global Healthcare Conference
Thursday, September 17 at 3:30 p.m. EDT, New York
Theravance, Inc., a royalty administration company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist partnershipagreement and the planned alliance agreement with Glaxo Group Limited (GSK).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
